iCo Therapeutics Appoints Chief Medical Officer

Aug 17, 2006, 01:00 ET from iCo Therapeutics Inc.

    VANCOUVER, Aug. 17 /PRNewswire/ - iCo Therapeutics Inc. announced today
 the appointment of Dr. Peter Hnik as Chief Medical Officer. Dr. Hnik is an
 ophthalmologist with a focus in glaucoma, neuro-ophthalmology, and deep
 industrial experience in retinal diseases such as age related macular
 degeneration and diabetic retinopathy.
     "Dr. Hnik's clinical background represents an enormous asset to our
 management team and its maturation," said Andrew Rae, iCo Therapeutics'
 President and Chief Executive Officer. "His expertise in not only
 ophthalmology but also in other medical fields strengthens our position as
 we continue to build our pipeline and develop clinical stage drugs for a
 range of new conditions affecting isolated biological environments."
     Prior to joining iCo Therapeutics, Dr. Hnik served as Associate
 Director of Clinical Research with QLT Inc., playing a critical role in
 designing and directing Visudyne clinical trials in AMD and diabetic
 retinopathy. Dr. Hnik was also heavily involved in the publication,
 in-licensing and pharmacovigilance activities for Visudyne.
     "iCo Therapeutics is a company with an innovative business model, a
 talented management team and experienced, active advisory boards. With
 these fundamental building blocks in place, I am very enthusiastic about
 the prospects for the Company and my role in the company's evolution", said
 Dr. Hnik.
     Dr. Hnik received his medical degree from the Medical Faculty of
 Charles University of Prague in 1981. After practicing for years at the Eye
 Clinic of the Charles University Hospital where he performed surgery and
 consultation in glaucoma and neuro-ophthalmology, Dr. Hnik later joined the
 Eye Clinic of the University of British Columbia as part of the glaucoma
 research group. He received his Master of Health Sciences degree from the
 University of British Columbia in 1999. He is a member of the Association
 for Research in Vision and Ophthalmology (ARVO), the American Academy of
 Ophthalmology (AAO), the European Society of Retina Specialists (EURETINA)
 and the Drug Information Association (DIA).
     iCo Therapeutics Inc. is an emerging, Vancouver-based biotechnology
 company focused on developing pre-existing drugs for a range of new
 conditions affecting isolated biological environments - areas such as the
 eye, spinal cord, or joints - where locally-administered application of
 these therapies would have minimal systemic distribution and fewer safety
     For more information, visit the company website at:
     CONTACT: Business Development Contact: Dr. John Clement, CT&DO, (778)
 688-0644; Finance/Investor Contact: Mr. John Meekison, CFO, (604) 602-9414;
 Media Contact: Amanda Smith, Principal, Smith Biotech, (778) 846-4116

SOURCE iCo Therapeutics Inc.